Takeda, the patient-focused global biopharmaceutical company, is pleased to announce the signing of a new Memorandum of Understanding (MoU) with the Saudi Gastroenterology Association (SGA). This partnership brings together Takeda’s global expertise in gastroenterology and SGA’s recognized local leadership, with the collective goal of advancing the quality of care for individuals living with Inflammatory Bowel Disease (IBD) across Saudi Arabia.
“As studies highlight the rising prevalence of IBD in Saudi Arabia, it is essential that our medical community has access to the most advanced knowledge, tools, and resources,” said Prof. Majid Almadi, President of the Saudi Gastroenterology Association. “This partnership with Takeda will support enhancing our ability to deliver high-quality care by equipping healthcare professionals with advanced education, global expertise, and the latest scientific insights.”
“This agreement represents another important step in our ongoing commitment to supporting healthcare transformation in Saudi Arabia,” said Khaled Sary, General Manager, West Gulf Cluster at Takeda. “By aligning global innovation with national priorities, we aim to play a meaningful role in developing sustainable, patient-centered solutions for IBD care.”
Beyond professional development, the partnership will champion environmental sustainability as part of both organizations’ dedication to corporate social responsibility. The MoU reflects a shared commitment to ensuring IBD patient care grows in step with international best practices and accommodates the needs of the Saudi population – demonstrating ongoing dedication to both patient well-being and a healthier planet.
This Memorandum of Understanding (MOU) strengthens the synergy between Takeda and SGA, reinforcing their ongoing collaboration in various aspects of continuous medical education for healthcare professionals involved in the care of IBD patients in Saudi Arabia. Through diverse channels, the initiative aims to enhance the quality of care and increase disease awareness across the Kingdom. Additionally, it remains essential to continue exploring opportunities for evidence generation by leveraging Saudi Arabia’s strong capabilities and the extensive expertise of both organizations in the field of IBD.
IBD, including Crohn’s Disease and Ulcerative Colitis, is increasingly prevalent in Saudi Arabia, shifting from a rare diagnosis in previous decades to a more common condition today. It is a lifelong, often debilitating disease, with symptoms that range from abdominal pain and weight loss to unpredictable flare-ups, posing significant challenges for disease management.
Takeda is addressing this growing challenge by offering practical solutions that support clinical practice and patient well-being. Through such locally tailored initiatives and a focus on real-world outcomes, the company is helping healthcare providers and patients manage IBD more effectively.
